Efficacy News and Research

RSS

Scientists discover a novel strategy to unmask cancer cells in high-risk neuroblastoma

High-risk neuroblastoma is one of the most aggressive forms of solid tumors affecting children, originating in the nervous system.

6 Oct 2026

Mini-GRID radiotherapy limits cellular senescence in glioma models

A new research paper was recently published in Volume 18 of Aging, titled "Spatially fractionated mini-GRID radiotherapy differentially modulates radiation-induced senescence in murine glioma and normal cells."

6 Oct 2026

Blue light treatment kills food poisoning bacteria on raw chicken

A low-power blue light could be the key to significantly reducing food poisoning caused by raw chicken in the UK, scientists at the University of Reading have found.

6 Oct 2026

Mount Sinai adopts automated data integration for oncology clinical trials

The Mount Sinai Tisch Cancer Center has transitioned its electronic health record (EHR)-to-clinical trial data integration technology from pilot to routine use across its cancer research program.

6 Oct 2026

New model predicts growth hormone therapy response in children with short stature

Idiopathic short stature (ISS) describes children whose height is substantially below the expected range for their age and sex without any identifiable medical cause.

5 Oct 2026

Many herbal toothpastes fell short on a key cavity-fighting ingredient

A study on herbal toothpastes reveals varying fluoride levels, antibacterial efficacy, and cytotoxicity, highlighting safety concerns in oral hygiene products.

5 Oct 2026

Patient navigators significantly improve postpartum care for low-income mothers

While the transition to motherhood can be challenging for anyone, barriers such as inadequate health literacy, unreliable transportation, navigating a complex health care system, limited access to childcare or insecure housing can be the tipping point between a new mom accessing needed care or going without it.

5 Oct 2026

Dr. GPCR and Eurofins Discovery join forces to advance GPCR drug discovery

Dr. GPCR, the global knowledge hub for G protein-coupled receptor (GPCR) research and education, today announced a strategic partnership with Eurofins Discovery, the drug discovery services side of the same group behind the Eurofins DiscoverX products many in the community already know.

From Eurofins Discovery 5 Oct 2026

CBL-514 injection reduces visceral and subcutaneous fat in trials

Details of a new injection that targets fat cells will be released at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2).

1 Oct 2026

Highlight Therapeutics presents positive Phase 2b topline results of intralesional BO‑112 in localized basal cell carcinoma as a late-breaker at EADV

Highlight Therapeutics, a clinical‑stage biotechnology company developing immune activators to transform the treatment of skin tumors, today announced positive results from the multicenter, single-arm Phase 2b SPOTLIGHT‑204 clinical trial evaluating BO‑112, a novel dsRNA-based intralesional treatment for patients with resectable primary low‑ and high‑risk basal cell carcinoma (BCC).

1 Oct 2026

Real-world data reveals higher reported GLP-1 side effects in female patients

The second of a Series of papers presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Obstetrics, Gynaecology & Women's Health discusses the wide-ranging issues relating to use of GLP-1 RA drug use in women.

1 Oct 2026

Early-onset type 2 diabetes trial demonstrates significant 24-week fat loss

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Regional Health Americas journal shows that in people who have developed early onset type 2 diabetes (EOT2D) (aged under 45 years), around half these T2D cases can be reversed with a low-energy diet combined with a structured exercise program.

1 Oct 2026

New mathematical model tracks how tumor environment impacts cancer therapies

Researchers from Mass General Brigham and the University of Cyprus have developed a sophisticated mathematical model to better understand how the tumor microenvironment affects the delivery and effectiveness of a new type of cancer therapy called an immunomodulatory antibody-drug conjugate (IM-ADC).

30 Sep 2026

Laverock Therapeutics announces in vivo programs in oncology and genetic medicine

Laverock Therapeutics (‘Laverock’), a biotechnology company developing disease-responsive advanced therapies through its unique, programmable gene control technology, today announces its in vivo programs spanning CAR-T and genetic medicine

From Laverock Therapeutics 30 Sep 2026

Petrelintide produces double-digit weight loss with fewer side effects

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Diabetes & Endocrinology shows that weekly injections with the new amylin-based obesity drug petrelintide can enable those treated to lose more than 10% of their body weight – generally lower than existing incretin-based (GLP-1 RA) drugs, but also with far fewer side effects.

29 Sep 2026

Exercise may reshape your gut microbiome to support recovery

Research reveals how exercise alters gut microbes, influencing recovery and proposing 'intestinal rehabilitation' for those with limited exercise capacity.

29 Sep 2026

An approved Ebola antibody may miss its mark against Bundibugyo virus

Researchers analyzed 44 Bundibugyo virus genomes and modeled how approved and experimental Ebola antibodies might bind the virus’s glycoprotein. The models predicted disrupted binding for Ebanga, conserved targets for MBP134, and different binding behavior for the complete Inmazeb cocktail than for two of its antibodies alone; laboratory tests are needed to determine whether these findings translate into treatment benefit.

28 Sep 2026

Five-treatment radiation provides excellent long-term prostate cancer control

Five-treatment stereotactic body radiation therapy (SBRT) provided excellent long-term cancer control with fewer urinary and sexual side effects than surgery in the first randomized trial to directly compare the treatments for localized prostate cancer.

28 Sep 2026

Triple combination therapy trial for HR+/HER2− breast cancer halts early due to toxicity concerns

HR+/HER2− breast cancer constitutes approximately 65–75% of all breast cancer cases worldwide. Although CDK4/6 inhibitors have substantially extended progression-free survival (PFS), up to 60% of patients derive no clinical benefit from these agents, underscoring the urgent need for more effective therapeutic strategies.

28 Sep 2026

Mediterranean rockrose extract shows strong potential against skin fungi

A polyphenol-rich extract from Cistus salviifolius, a Mediterranean rockrose species traditionally used to treat skin conditions, has shown fungicidal activity against several dermatophytes, the fungi responsible for superficial infections of the skin, hair and nails.

28 Sep 2026